Skip to main content
IMMUTEP LIMITED logo

IMMUTEP LIMITED — Investor Relations & Filings

Ticker · IMM ISIN · AU000000IMM6 LEI · 529900OL6C5CY5P8BH38 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,780 across all filing types
Latest filing 2025-09-11 Major Shareholding Noti…
Country AU Australia
Listing ASX IMM

About IMMUTEP LIMITED

https://www.immutep.com

Immutep Limited focuses on the development of novel immunotherapy treatments for cancer and autoimmune diseases, specifically targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. The company's lead therapeutic candidate is eftilagimod alpha (efti), a first-in-class soluble LAG-3 protein and MHC class II agonist. Efti functions by activating antigen-presenting cells, which in turn triggers a robust T cell response against tumors. It is currently being evaluated in clinical trials for multiple solid tumor indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, frequently in combination with other anti-cancer agents. The pipeline also includes IMP761, an agonist antibody designed to suppress overactive immune responses in autoimmune conditions. The company's technology utilizes the LAG-3 protein's role in immune regulation to create targeted therapeutic interventions.

Recent filings

Filing Released Lang Actions
Becoming a substantial holder 18 pages 895.8KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act 2001 Section 671B, which pertains to the notice of an initial substantial holder. It details the substantial holder's name, voting power, relevant interests, registered holders, consideration paid, associates, and addresses. The content is focused on notifying the market and regulators about a significant shareholding position acquired by JPMorgan Chase & Co. and its affiliates. This type of filing is a Major Shareholding Notification, which is used to disclose when a party acquires a substantial interest in a company, typically crossing a regulatory threshold. The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding. Therefore, the correct classification is Major Shareholding Notification (MRQ). The document length and detail support a high confidence in this classification.
2025-09-11 English
EFTISARC-NEO data accepted for oral presentation at CTOS 2 pages 146.4KB
Investor Presentation Classification · 85% confidence The document is a company announcement about an abstract acceptance for oral presentation at a scientific conference (CTOS 2025 Annual Meeting). It details the presentation topic, session, presenter, and date, and mentions that presentation slides will be available on the company's website after the event. There is no financial data, regulatory filing, or report attached or referenced. The content is focused on investor and media information about the upcoming presentation rather than a financial or regulatory report. The document length is 3911 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Investor Presentation (IP) announcement or related communication, but since it is an announcement of a presentation rather than the presentation itself, and it is not a full investor presentation document, the closest fitting category is Regulatory Filings (RNS) as a general announcement. However, given the specific focus on the presentation and investor/media contact details, the best fit is Investor Presentation (IP).
2025-09-07 English
Appendix 4E & 2025 Full Year Statutory Accounts 93 pages 5.5MB
Annual Report Classification · 100% confidence The document is titled 'Preliminary final report' and includes an Appendix 4E, which is a regulatory form used in Australia for preliminary final reports. It covers the full fiscal year ended 30 June 2025, with detailed financial results, explanations, and a comprehensive Annual Report attached. The text includes a Chairman's letter, detailed operational review, financial statements, auditor's report, and governance information, all typical components of an Annual Report (10-K equivalent). The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or certification. Therefore, this document is classified as an Annual Report (10-K).
2025-08-28 English
FDA feedback received for head & neck cancer in CPS below 1 2 pages 108.8KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about receiving positive feedback from the FDA regarding clinical development of a drug. It discusses regulatory feedback, clinical trial phases, and future development plans but does not contain financial data, earnings, or detailed report content. It is a regulatory announcement about clinical development progress and FDA feedback, not a financial report or earnings release. The document is relatively short (4897 characters) and serves as a news release or regulatory update. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-08-04 English
Immutep Quarterly Activities Report and Appendix 4C 10 pages 563.6KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Immutep Quarterly Activities Report & Appendix 4C Q4 FY25' and provides detailed updates on clinical trials, development programs, intellectual property, senior management changes, and a comprehensive cash flow summary for the quarter ended 30 June 2025. It includes actual financial data such as cash flows from operating and investing activities, payments to related parties, and cash balances. The presence of the Appendix 4C, which is a quarterly cash flow report required by the ASX Listing Rules, confirms this is a quarterly financial report. The document is not merely an announcement or a brief summary but contains substantive financial data and operational updates for the quarter. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-07-29 English
TACTI-004 trial in progress poster to be presented at WCLC 2 pages 260.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing an upcoming poster presentation at a medical conference about a clinical trial in progress (TACTI-004 Phase III trial). It provides details about the trial design, the presentation session, and background information about the drug and company. There are no financial statements, regulatory filings, voting results, or management changes. The document is an announcement of a scientific presentation rather than a financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2025-07-28 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.